^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ampulla of Vater Carcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/27/2023
    Excerpt:
    Ampullary Adenocarcinoma….Poor PS:...Intestinal Type, For select patients with ECOG 2 consider multi-agent regimens:...5-FU + leucovorin ± bevacizumab.
    Secondary therapy:
    5-fluorouracil + leucovorin calcium